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mkaddah1973200Abstract A rapid, sensitive and simple spectroﬂuorimetric method was developed for the
estimation of atorvastatin. In this method, the native ﬂuorescence characteristics of atorvastatin
have been studied in both acidic and basic media. High sensitivity was obtained with 5% acetic acid
at 389 nm using 276 nm for excitation. Regression analysis showed a good correlation coefﬁcient
(r¼0.9995) between ﬂuorescence intensity and concentration over the range of 1.5–4 mg/mL with
detection limit of 0.012 mg/mL. The proposed method was successfully applied to the analysis of
atorvastatin in pure and pharmaceutical dosage forms with average recovery of 100.2970.47%.
The results were compared favorably with those of the reported method.
& 2012 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Atorvastatin calcium (Fig. 1) is a calcium (bR, dR)-
2-(r-ﬂuorophenyl)-b, d-dihydroxy-5-isopropyl-3-phenyl-4-ersity. Production and hosting
n Jiaotong University.
sevier
8821586.
4@yahoo.com(phenylcarbamoyl) pyrrole-1-hepatanoic acid(1:2) trihydrate.
C66H68CaF2N4O10  3H2O¼1209.4 [1], which is one of the
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase inhibitor (a statin). It is a lipid regulating drug with
actions on plasma lipids similar to those of simvastatin. It is
used to reduce LDL-cholesterol, apolipoprotein B, and trigly-
cerides, and to increase HDL-cholesterol in the treatment of
hyperlipidaemias [2–4].
Several studies have been reported for the determination of
atorvastatin in pharmaceutical and/or biological ﬂuids includ-
ing spectrophotometric methods [5–8], electrophoresis [9,10],
polarographic method [11] and chromatographic methods
with different detectors [12–20]. To the best of our knowledge,
none of the reported procedures describe spectroﬂuorimetric
method for the determination of atorvastatin. Thus, an
attempt was made to develop a new, rapid, sensitive and
validated spectroﬂuorimetric procedure for the determination
of atorvastatin.
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Figure 1 Chemical structure of atorvastatin.
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2.1. Materials and reagents
Atorvastatin calcium powder (Batch No. 1617357) was kindly
supplied by El-Oboure Pharmaceutical Company. Atorvastatin
tablets (each tablet contains 20 mg of atorvastatin), manufac-
tured by Pﬁzer (Batch No. 084540), were purchased from the
Egyptian market. All reagents and chemicals used were of
analytical grade and all were purchased from Sigma–Aldrich
(Steinheium, Germany). Glass distilled water was further puriﬁed
using Milli-Q water puriﬁcation system (Millipore, Bedford, MA,
USA). Buffers of different pH values were prepared as prescribed
in British Pharmacopeia [21]: Acetate buffer (pH 2.45): Mix 200 mL of 1 M hydro-
chloric acid with 200 mL of 1 M sodium acetate and
dilute to 1000 mL with water. Immediately before use
adjust the pH to 2.45 by the addition of 1 M hydrochloric
acid or 1 M sodium acetate, as required. Acetate buffer (pH 2.8): Dissolve 4 g of anhydrous
sodium acetate in about 840 mL of water, add sufﬁcient
glacial acetic acid to adjust the pH to 2.8 (about 155 mL)
and dilute to 1000 mL with water. Acetate buffer (pH 3.4): Mix 5 volumes of 0.1 M sodium
acetate with 95 volumes of 0.1 M acetic acid. Acetate buffer (pH 4.5): Dissolve 77.1 g of ammonium
acetate in water, add 70 mL of glacial acetic acid and
dilute to 1000 mL with water. Acetate buffer (pH 5.0): Dissolve 13.6 g of sodium acetate
and 6 mL of glacial acetic acid in sufﬁcient water to
produce 1000 mL. Acetate buffer (pH 6.0): Dissolve 100 g of ammonium
acetate in 300 mL of water, add 4.1 mL of glacial acetic
acid, adjust the pH, if necessary, using 10 M ammonia or
5 M acetic acid and dilute to 500 mL with water Phosphate buffers (pH 5.8–8.0): Mix 50 mL of 0.2 M
potassium dihydrogen orthophosphate with different
quantities of 0.2 M sodium hydroxide and dilute to
200 mL with water. Phosphate buffer (pH 9.0): Dissolve 1.74 g of potassium
dihydrogen orthophosphate in 80 mL of water, adjust the
pH, if necessary, with 1 M potassium hydroxide and
dilute to 100 mL with water. Borate buffer (pH 10): To 50 mL of a solution containing
0.6189 g of boric acid and 0.7456 g of potassium chloride
add 36.85 mL of 0.2 M sodium hydroxide, adjust pH to
10 using 0.2 M sodium hydroxide and dilute with water to
200 mL.2.2. Standard solutions
Stock solutions of atorvastatin were prepared by dissolving
the compound in methanol at concentration of 200 mg/mL.
2.3. Apparatus
Fluorescence spectra and measurements were recorded using
PerkinElmer luminescence spectrometer LS 45 (UK),
equipped with 150 W Xenon arc lamp. The slit widths for
both excitation and emission monochromators were set at
10 nm. A pH-meter (Mettler-Toledo GmbH, Switzerland) was
used for pH adjustment.
2.4. Procedures
2.4.1. Spectroﬂuorimetric method using acetate buffer (pH 3.4)
Different aliquots of atorvastatin stock solution (200 mg/mL in
methanol) ranging from 50 to 100 mL were transferred to 5 mL
volumetric ﬂask. One milliliter of acetate buffer (pH 3.4) was
added to each volumetric ﬂask. The solutions were diluted to
volume with ethanol: water (50:50, v/v), shaken vigorously
and immediately measured. The ﬂuorescence intensity was
measured at 389 nm (lEx¼276 nm).
2.4.2. Spectroﬂuorimetric method using 5% acetic acid (pH 2.5)
Different aliquots of atorvastatin stock solution (200 mg/mL
in methanol) ranging from 50 to 200 mL were transferred to
10 mL volumetric ﬂask. The solutions were diluted to volume
M.M.K. Sharaf El-Din et al.202with acetic acid (5%, v/v), shaken vigorously and immediately
measured. The ﬂuorescence intensity was measured at 389 nm
(lEx¼276 nm).
2.4.3. Spectroﬂuorimetric method using methanol
Different aliquots of atorvastatin stock solution (200 mg/mL in
methanol) ranging from 25 to 125 mL were transferred to a
10 mL volumetric ﬂask. The solutions were diluted to volume
with spectroscopic methanol, shaken vigorously and immedi-
ately measured. The ﬂuorescence intensity was measured at
389 nm (lEx¼276 nm).
2.4.4. Analysis of Lipitors tablets
Ten Lipitors tablets were weighed, crushed and mixed in
a mortar. An amount of powdered mass equivalent to 20 mg
of atorvastatin was weighed and transferred to a 50 mL
conical ﬂask, the drug from powder was dissolved and
extracted with methanol. To ensure complete extraction of
drug it was sonicated for 15 min. The extract was ﬁltered, and
residue was washed with methanol. The extract and washing
solution were pooled and transferred to a 100 mL volumetric
ﬂask and volume was made with methanol. This solution was
analyzed as described in the general analytical procedure
(Section 2.4.)248.6 247.2
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Figure 3 Effect of different buffers on the ﬂuorescence intensity
of 2.5 mg/mL atorvastatin.3. Results ad discussion
3.1. Spectroﬂuorimetric method using acetate buffer
(pH 3.40)
Atorvastatin presents a native ﬂuorescence with slight differ-
ences in both acidic and basic media as shown in Fig. 2.
The excitation and emission spectra at pH 3.4 using acetate
buffer (spectra 3, 4) and at pH 9.0 using phosphate buffer
(spectra 1, 2) are shown in Fig. 2. As can be seen the
ﬂuorescence of atorvastatin in acetate buffer (pH 3.4) is
slightly higher than that in phosphate buffer (pH 9.0). The
emission and excitation wavelengths were recorded at 389 and
276 nm, respectively.
To regulate the pH, different buffers; acetate, phosphate
and borate buffers prepared as described in British200.0 250 300 350 400 450 500 540.0
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Figure 2 The excitation and emission spectra at pH 9 using
phosphate buffer (spectra 1, 2) and at pH 3.4 using acetate buffer
(spectra 3, 4) of 2 mg/mL atorvastatin.Pharmacopoeia, were tested. The variation of the emission
intensity at 389 nm (lEx¼276 nm) of atorvastatin versus the
pH of the different buffers is shown in Fig. 3. The maximum
ﬂuorescence intensity was recorded with acetate buffer; there-
fore acetate buffer was chosen as the best buffer to regulate
the pH of atorvastatin.
The effect of acetate buffer (pH 3.4) on the ﬂuorescence
intensity of atorvastatin expressed by the number of milliliters of
buffer added to a 5 mL volumetric ﬂask is shown in Fig. 4. As can
be seen one milliliter of acetate buffer is sufﬁcient to produce
the maximum ﬂuorescence of atorvastatin. Also the effect of
the measuring time was examined between 5 and 30 min. The
ﬂuorescence slightly decreased as the time increased. Therefore,
immediate measurement is preferable. The inﬂuence of the
temperature was studied between 20 and 50 1C and it could
be observed that the ﬂuorescence intensity decreased when the
temperature increased. For that reason 20 1C was chosen for
further experiences.3.2. Spectroﬂuorimetric method using 5% acetic acid
The different experimental parameters that affect the ﬂuore-
scence intensity of atorvastatin in acetic acid were carefully150
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Figure 4 Effect of acetate buffer (pH 3.4) on the ﬂuorescence
intensity of 2.5 mg/mL atorvastatin.
169
170
171
172
173
174
175
176
177
178
179
180
0% 1% 2% 3% 4% 5% 6% 7% 8%
Fl
uo
re
se
nc
e 
in
te
ns
ity
Concentration of acetic acid (v/v)
Figure 5 Effect of acetic acid concentration on the ﬂuorescence intensity of 1.5 mg/mL atorvastatin.
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337.51 335.329
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Figure 6 Effect of different solvents on the ﬂuorescence intensity
of 1.5 mg/mL atorvastatin.
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on the ﬂuorescence intensity of atorvastatin expressed as
percentage (v/v) is shown in Fig. 5. As can be seen 5% acetic
acid is sufﬁcient to produce the maximum ﬂuorescence of
atorvastatin. Also the effect of the measuring time was
examined between 5 and 30 min. The ﬂuorescence slightly
decreased as the time increased. Therefore, immediate mea-
surement is preferable. The inﬂuence of the temperature was
studied between 20 and 50 1C and it could be observed that the
ﬂuorescence intensity decreased when the temperature
increased. For that reason 20 1C was chosen for further
experiences.3.3. Spectroﬂuorimetric method using methanol
The ﬂuorescence intensities of atorvastatin in different sol-
vents are shown in Fig. 6. It could be observed that methanol
or ethanol increases the signal of ﬂuorophore.
The ﬂuorescence characteristics of atorvastatin have been
established in acidic, basic and neutral media. When compar-
ing the three methods with each other, they showed a good
linearity in all cases. A comparison also revealed that the using
of 5% acetic acid or methanol as a co-solvent was much better
than the using of acetate buffer due to their higher sensitivity.3.4. Validation of the method
3.4.1. Linearity, detection and quantiﬁcation limits
Satisfactory linearity (r40.999) was obtained for the three
proposed spectroﬂuorimetric methods. The analytical para-
meters of the proposed methods are summarized in Table 1.
The detection limit and the quantiﬁcation limit were calculated
using the following equation [22]:
DL; QL¼ ðF  SDÞ=b
where F is the factor of 3.30 and 10 for DL and QL,
respectively. SD is the standard deviation of the blank and b
is the slope of the regression line. The estimated limits were
veriﬁed by analyzing a suitable number of samples containing
the analyte at the corresponding concentrations.
3.4.2. Precision and accuracy
Samples of pure atorvastatin were prepared and tested using
the proposed procedures. The results obtained for pure drugs
are given in Table 2. To ascertain the accuracy of the proposed
procedures, they were successfully applied for the determina-
tion of atorvastatin in Lipitors tablets, as presented in
Table 3.
3.5. Statistical analysis of the results in comparison with the
ofﬁcial methods
The results of the analysis of the drug were compared
statistically by the Student’s t-test and the variance ratio
F-test with those obtained by the reported methods [5]. The
Student’s t-values at 95% conﬁdence level did not exceed the
theoretical values, indicating that there was no signiﬁcant
difference between the proposed methods and the reported
method. It was also noticed that the variance ratio F-values
calculated for p¼0.05 did not exceed the theoretical values,
indicating that there was no signiﬁcant difference between the
precision of the proposed methods and the reported method.
The results are given in Table 4.4. Conclusion
In this work three spectroﬂuorimetric methods for the deter-
mination of atorvastatin are proposed. All of them present
Table 1 Regression characteristics and assay parameters of the proposed methods.
Parameters Spectroﬂuorimetric method
using acetate buffer (pH 3.4)
Spectroﬂuorimetric method
using 5% acetic acid
Spectroﬂuorimetric
method using methanol
Linearity range (mg/mL) 1.50–4.00 1.00–4.00 0.50–3.00
Detection limit (DL) (mg/mL) 0.03 0.01 0.01
Quantiﬁcation limit (QL) (mg/mL) 0.75 0.13 0.13
Regression equationn
Slop (b) 97.14 51.60 111.39
Intercept (a) 46.09 16.14 23.32
Correlation coefﬁcients (r) 0.9996 0.9998 0.9995
ny¼aþbx where y is the ﬂuorescence and x is the concentration.
Table 2 Determination of atorvastatin by the proposed spectroﬂuorimetric methods.
Spectroﬂuorimetric method using acetate
buffer (pH 3.4)
Spectroﬂuorimetric method using 5%
acetic acid
Spectroﬂuorimetric method using
methanol
Known
concentration
(mg/mL)
Concentration
found (mg/mL)
Recovery
(%)
Known
concentration
(mg/mL)
Concentration
found (mg/mL)
Recovery
(%)
Known
concentration
(mg/mL)
Concentration
found (mg/mL)
Recovery
(%)
2.00 1.96 98.04 1.50 1.48 98.87 0.50 0.51 102.46
2.50 2.54 101.57 2.00 2.03 101.35 1.00 1.02 101.68
3.00 3.01 100.40 2.50 2.48 99.13 1.50 1.49 99.11
3.50 3.52 100.44 3.00 3.02 100.63 2.00 1.97 98.65
4.00 3.97 99.32 3.50 3.51 100.23 2.50 2.48 99.21
4.00 3.99 99.66 3.00 3.04 101.32
Mean 99.95 100.20 99.99
N 5.00 6.00 6.00
SD 1.78 0.73 1.95
R.S.D. (%) 1.33 0.86 1.40
Table 3 Determination of atorvastatin in Lipitors tablets (20 mg) by the proposed spectroﬂuorimetric methods.
Spectroﬂuorimetric method using acetate
buffer (pH 3.4)
Spectroﬂuorimetric method using 5%
acetic acid
Spectroﬂuorimetric method using
methanol
Known
concentration
(mg/mL)
Concentration
found (mg/mL)
Recovery
(%)
Known
concentration
(mg/mL)
Concentration
found (mg/mL)
Recovery
(%)
Known
concentration
(mg/mL)
Concentration
found (mg/mL)
Recovery
(%)
2.00 1.97 98.62 2.00 1.99 99.75 1.00 1.03 102.92
2.50 2.59 103.44 3.00 3.02 100.60 1.50 1.47 98.03
3.00 3.15 105.10 4.00 4.02 100.53 2.00 1.96 98.18
3.50 3.59 102.67 2.50 2.54 101.47
4.00 3.99 99.95 3.00 3.12 104.09
Mean 101.96 100.29 100.94
N 5.00 3.00 5.00
SD 2.64 0.47 2.75
R.S.D. (%) 1.16 0.27 1.22
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Table 4 Statistical analysis of pure atorvastatin by the proposed spectroﬂuorimetric methods.
Items Spectroﬂuorimetric method
in acetate buffer (pH 3.4)
Spectroﬂuorimetric method
using 5% acetic acid
Spectroﬂuorimetric
method using methanol
Reported method [5]
Mean (%) 99.95 99.98 100.41 100.97
N 5.00 6.00 6.00 7.00
V 1.78 0.88 2.57 1.47
SD 1.33 0.94 1.60 1.21
R.S.D. (%) 0.60 0.38 0.65 0.45
F-test 1.23 (4.53)a 1.63 (4.95)a 1.77 (4.39)a
Student’s t-test 1.34 (2.228)a 1.57 (2.179)a 0.70 (2.179)a
aThe ﬁgures in parenthesis are the corresponding tabulated values at p¼0.05.
Validated spectroﬂuorimetric method for the determination of atorvastatin 205several advantages, such as rapid preparation of the samples
and short time of analysis where all the measurements can be
made just after preparation.
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